Dupilumab Continues to Show Promise in Eosinophilic Esophagitis

(MedPage Today) -- PHOENIX -- Nearly three-fifths of patients with eosinophilic esophagitis (EoE) achieved remission after treatment with dupilumab (Dupixent), researchers reported. In a 6-month study, 58.8% of adults and adolescents treated...
Source: MedPage Today Allergy - Category: Allergy & Immunology Source Type: news